No evidence for evolution of protease inhibitor resistance from standard genotyping, after three years of treatment with darunavir/ritonavir, with or without nucleoside …
AIDS research and human retroviruses, 2012•liebertpub.com
Editor: In several recent studies, the risk of treatmentemergent drug resistance has been
lower for patients using combinations of two nucleoside analogues plus a boosted protease
inhibitor (PI), compared to two nucleoside analogues plus a nonnucleoside. 1–3 However,
there are concerns that if patients with full HIV RNA suppression are switched to protease
inhibitor monotherapy, there could be an increased risk of elevations in HIV RNA and
subsequent resistance to
lower for patients using combinations of two nucleoside analogues plus a boosted protease
inhibitor (PI), compared to two nucleoside analogues plus a nonnucleoside. 1–3 However,
there are concerns that if patients with full HIV RNA suppression are switched to protease
inhibitor monotherapy, there could be an increased risk of elevations in HIV RNA and
subsequent resistance to
Editor: In several recent studies, the risk of treatmentemergent drug resistance has been lower for patients using combinations of two nucleoside analogues plus a boosted protease inhibitor (PI), compared to two nucleoside analogues plus a nonnucleoside. 1–3 However, there are concerns that if patients with full HIV RNA suppression are switched to protease inhibitor monotherapy, there could be an increased risk of elevations in HIV RNA and subsequent resistance to
Mary Ann Liebert